Бисопролол и хроническая сердечная недостаточность


А.А. Кириченко

Кафедра терапии ГБОУ ДПО РМАПО, Москва
Терапия блокаторами β-адренергических рецепторов приводит к уменьшению риска смерти и тяжелых сосудистых осложнений у больных хронической сердечной недостаточностью (ХСН). Особенно значимо влияние лечения β-адреноблокаторов на риск развития фатальных желудочковых аритмий в группах пациентов с высоким риском внезапной смерти. Бисопролол обладает хорошей биодоступностью, длительным периодом полувыведения, сбалансированным клиренсом, метаболически нейтрален. Высокая эффективность и хорошая переносимость препарата выдвинули его в группу основных средств, рекомендованных к применению пациентами с ХСН.

Литература



  1. Goldstein S. β-blocking drugs and coronary heart disease. Cardiovascю Drugs Therю 1997;71:219–25.

  2. Baker J.G. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br. J. Pharmacol. 2005;144(3):317–22.

  3. Nuttall S.L, Routledge H.C., Kendall M.J. A comparison of the beta1–selectivity of three beta–blockers. J. Clin. Pharmacol. 2003;28(3);179–86.

  4. Brixius K., Bundkirchen A., Bolck B. et al. nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br. J. Pharmacol. 2001;133(8):1330–38.

  5. Leopold G., Pabst J., Ungethum W., Buhring K.U. Basic pharmacokinetics of bisoprolol, a new highly beta 1 selective adrenoreceptor antagonist. J. Clin. Pharmacol. 1986;26:616–21.

  6. Leopold G, Kutz K. Bisoprolol: pharmacokinetic profile. Rev. Contemp. Pharmacother. 1997;8:35–43.

  7. Brode O.-E. The pharmacology of bisoprolol. Rev. Contemp. Pharmacother. 1997;8:21–33.

  8. Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J. Cardiovasc. Pharmacol. 1986;8(Suppl.11):S16–S20.

  9. Cheung W.K., Begg E., dutta A., et al. Dose proportionality of bisoprolol in man. Pharm. Res. 1988;5(Suppl):S159.

  10. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

  11. Сидоренко Б.А. β-блокаторы: современныне аспекты применения в кардиологии. Кардиология. 1998;2:84–96.

  12. Hjalmarson A. cardiprotection with beta–adrenoreceptor blockers. Does lipophilicity matter? Basic Res. Cardiol. 2000;95(Supll 1):I41–45.

  13. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999;353:9–13.

  14. Иваненко В.В., Рязанцева Н.В., Тарасов Д.Л. и др. Эффект бета-блокатора бисопролола на функцию спящего миокарда у больных с хронической сердечной недостаточностью ишемической этиологии. Кардиология. 2004;44(7):57–61.

  15. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study. Circulation. 1994;90:l765–73.

  16. Funk–Bentano C., Lancart R., Lehenzey J.Y., et al. Predictors of medical events in patients enrolled in the Cardiac Insufficiency Bisoprolol Study II (CIBIS–II); a study of the interaction between beta0blocker therapy and occurrence of critical events using analysis of competative risks. Am. Heart J. 2000;139:262–71.

  17. Сыркин А.Л., Добровольский А.В. Место бисопролола в лечении заболеваний сердечно-сосудистой системы. Русский медицинский журнал. 2010;18(22):1352–55.

  18. Упницкий А.А. Исследования с бисопрололом при хронической сердечной недостаточности: CIBIS, CIBIS II и CIBIS III. Качественная клиническая практика. 2008;2:13–21.

  19. Терещенко С.Н. Бета-блокаторы у больных с относительными противопоказаниями к их применению // Журнал сердечная недостаточность. 2003;4(№ 1[17]):55–6.

  20. Aronow W.S. Treatment of heart failure in older persons. Dilemmas with coexisting conditions: diabetes mellitus, chronic obstructive pulmonary disease, and arthritis. Congest. Heart. Fail. 2003;9(3):142–47.

  21. Camsari A., Arikan S., Avan C., et al. Metoprolol, a beta-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart. Vessels. 2003;18(4):188–92.

  22. Gelbrich G., Edelmann F., Inkrot S., et al. Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly. Int. J. Cardiol. 2012;155(1):160–66.

  23. Wai B., Kearney L.G., Hare D.L. et al. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc. Diabetol. 2012;11(1):14.

  24. Ellerbeck E.F., Jencks S.F., Randorf M.J., et al. Quality of care for Medicare patients with acute myocardial infarction:A for–state pilot study from the cooperative cardiovascular project. JAMA. 1995;273:1509–14.

  25. Brand D.A., Newcomer L.N., Freiberger A., tian H. Cardiologist’s practices compared with practice guidelines: use of beta–blocade after acute myocardial infarction. J. Am. Coll. Cardiol. 1995;26:1432–36.

  26. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta–blocade on mortality in high–risk and low – risk patients after myocardial infarction. N. Engl. J. Med. 1998;339:489–97.

  27. Chen J., Redfort M.J., Wang Y., et al. Effectiveness of beta–blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J. Am. Coll. Cardiol. 2001;7:1950–56.

  28. Терещенко С.Н., Павликова Е.П., Сивков В.И., Моисеев В.С. Применение селективного бета-адреноблокатора бисопролола у больных острым инфарктом миокарда и сопутствующим хроническим обструктивным бронхитом. Кардиология, 2000;9:42–4.

  29. Dorow L., Bethge H., Tonnesmann U. Effects of single oral doses of bisoprolol and atenolo on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur. J. Clin. Pharmacol. 1986;31:143–47.

  30. Chatterjee S.S. the cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. J. Cardiovasc. Pharmacol. 1986;8(Suppl 1):74–77.

  31. Kjeksus J.K., Gilpin E., Cali G., et al. Diabetic patients and beta–blockers after acute myocardial infarction. Eur. Heart J. 1990;11:43–50.

  32. Forman D.E., Gutierrez Bernal J.L., Wei J.I. Management of acute myocardial infarction in the very elderly. Am. J. Med. 1992;93:315–26.

  33. Chen J., Marciniac T.A., Radford M.J., et al. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. JACC. 1999;34:1388–94.

  34. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in tipe 2 diabetes: UKPDS 38. B Med. J. 1998;317:703–13.

  35. Jonas M., Reicher–Reiss H., Boyko V., et al. Usefullness of beta–blocker therapy in patients with noninsulin dependent diabetes mellitus and coronary arthery disease. Bezafibrate infarction prevention (BIP) Study Groop. Am. J. Cardiol. 1996;77:1273–77.

  36. Owada A., Suda S., Hata T., Miyake S. The effect of bisoprolol, a selective beta1-blocker, on glucose metabolism by long–term administration in essential hypertension. Clin. Exp. Hypertens. 2001;23(4):305–16.

  37. Janka H.U., Ziegler A.G., Disselhoff G., Mehnert H. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J. Cardiovasc. Pharmacol. 1986;8(Suppl 11):S96–9.

  38. Heinemann I., Heise T., Ampudia J., et al. Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity. Eur. Heart J. 1995;25:595–600.

  39. Schouten O., Poldermans D., Visser L. et al. Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study. Am Heart J. 2004;148(6):1047–52.

  40. Vulpis V., Antonacci A., Prandi P. et al. The effect of bisoprolol and atenolo on glucose metabolism in hypertensive patients with non–insulin dependent diabetes mellitus. Minerva Med. 1991;82:189–93.

  41. Fogari R., Zoppi A., Tettamanti F., et al. Beta–blocker effects on plasma lipids in antihypertensive therapy: importance of the duratuon of treatment and lipid status befor treatment. J. Cardiovasc. Pharmacol. 1990;16(Suppl 5):S76–S80.

  42. Frithz G., Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur. J Clin. Pharmacol. 1987;32:77–80.

  43. Wikstrand J., Wedel H., Castagno D., McMur-ray J.J. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. J Intern Med. 2014 Feb;275(2):134–43. doi: 10.1111/joim.12141. Epub 2013.

  44. Prisant L.M., Weir M.R., Frishman W.H., et al. Self reported sexual dysfunction in men and women treated with bisoprolol, hydrochlorothiazide, enelapril,amlodipine, placebo or bisoprolol/hydrochlorothiazide. J. Clin. Hypertens (Greenwich). 1999;1(1):22–6.

  45. Bulpitt C.J, Connor M. Schulte M., Fletcher A.E. Bisiprolol and nifedipine retard in elderly hypertensive patients: effect on quality of life. J. Hum. Hypertens. 2000;14(3):205–12.


Об авторах / Для корреспонденции


А.А. Кириченко – Кафедра терапии ГБОУ ДПО РМАПО, Москва


Похожие статьи


Бионика Медиа